Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 2
2004 4
2005 5
2006 1
2007 1
2008 5
2009 6
2010 1
2012 1
2014 4
2015 5
2016 6
2017 1
2018 3
2019 2
2020 7
2021 3
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: maurer m. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Break-out session highlights.
Myhr KM, Mäurer M, Ginés MM, Esposito F, Linker R. Myhr KM, et al. Among authors: maurer m. Neurodegener Dis Manag. 2017 Nov;7(6s):45-49. doi: 10.2217/nmt-2017-0042. Neurodegener Dis Manag. 2017. PMID: 29143586
Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
Appeltshauser L, Junghof H, Messinger J, Linke J, Haarmann A, Ayzenberg I, Baka P, Dorst J, Fisse AL, Grüter T, Hauschildt V, Jörk A, Leypoldt F, Mäurer M, Meinl E, Michels S, Motte J, Pitarokoili K, Stettner M, Villmann C, Weihrauch M, Welte GS, Zerr I, Heinze KG, Sommer C, Doppler K. Appeltshauser L, et al. Among authors: maurer m. Brain. 2023 May 2;146(5):1932-1949. doi: 10.1093/brain/awac418. Brain. 2023. PMID: 36346134 Free PMC article.
[New master's program: multiple sclerosis management].
Voigt I, Stadelmann C, Meuth SG, Schipp B, Flachenecker P, Mäurer M, Funk RHW, Ramisch F, Niemeier J, Ziemssen T. Voigt I, et al. Among authors: maurer m. Wien Med Wochenschr. 2022 Nov;172(15-16):383-391. doi: 10.1007/s10354-021-00900-3. Epub 2022 Feb 2. Wien Med Wochenschr. 2022. PMID: 35107651 Free PMC article. German.
Animal models of immune-mediated neuropathies.
Mäurer M, Gold R. Mäurer M, et al. Curr Opin Neurol. 2002 Oct;15(5):617-22. doi: 10.1097/00019052-200210000-00013. Curr Opin Neurol. 2002. PMID: 12352006 Review.
71 results